The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Issue 7 (2nd August 2014)

• Record Type: Journal Article
• Authors: Prada‐Villaverde, Arancha; Esquivel, Jesus; Lowy, Andrew M.; Markman, Maurie; Chua, Terence; Pelz, Joerg; Baratti, Dario; Baumgartner, Joel M.; Berri, Richard; Bretcha‐Boix, Pedro; Deraco, Marcello; Flores‐Ayala, Guillermo; Glehen, Olivier; Gomez‐Portilla, Alberto; González‐Moreno, Santiago; Goodman, Martin; Halkia, Evgenia; Kusamura, Shigeki; Moller, Mecker; Passot, Guillaume; Pocard, Marc; Salti, George; Sardi, Armando; Senthil, Maheswari; Spiliotis, John; Torres‐Melero, Juan; Turaga, Kiran; Trout, Richard
• Is Part Of: Journal of surgical oncology. Volume 110:Issue 7(2014:Dec. 01)
• Page Start: 779
• Page End: 785
• Publication Date: 2014-08-02
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23728
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jso23728-sec-0001" sec-type="section"> <title>Background</title> <p>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.</p> </sec> <sec id="jso23728-sec-0002" sec-type="section"> <title>Methods</title> <p>The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).</p> </sec> <sec id="jso23728-sec-0003" sec-type="section"> <title>Results</title> <p>Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (<italic>P</italic> = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (<italic>P</italic> = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (<italic>P</italic> = 0.427).</p> </sec> <sec id="jso23728-sec-0004" sec-type="section"> <title>Conclusion</title> <p>These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Propsective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin. <italic>J. Surg. Oncol. 2014 110:779–785</italic>. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>